Investigating the Neuroimmune, Cerebrovascular, and Cognitive Disturbances Associated with SARS‑CoV‑2 Infection: A Systematic Review of Post‑Acute Outcomes

Investigating the Neuroimmune, Cerebrovascular, and Cognitive Disturbances Associated with SARS‑CoV‑2 Infection: A Systematic Review of Post‑Acute Outcomes | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Systematic Review Investigating the Neuroimmune, Cerebrovascular, and Cognitive Disturbances Associated with SARS‑CoV‑2 Infection: A Systematic Review of Post‑Acute Outcomes Htet Lin Aung This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-6183335/v2 This work is licensed under a CC BY 4.0 License Status: Posted Version 2 posted You are reading this latest preprint version Show more versions Abstract Background SARS-CoV-2, initially identified as a respiratory pathogen, has emerged as a significant driver of neurological morbidity in the post-acute phase of infection. A substantial body of evidence underscores persistent neuroimmune dysregulation, cerebrovascular injury, and cognitive impairment as critical contributors to long-term disability among COVID-19 survivors. However, the mechanistic interplay between these processes and their clinical implications remains incompletely characterized. Objectives This systematic review and meta-analysis aim to (1) elucidate the pathophysiological mechanisms underlying post-acute neurological outcomes of COVID-19, (2) evaluate the prevalence and clinical spectrum of neuroimmune, cerebrovascular, and cognitive disturbances using both qualitative and quantitative data, and (3) propose strategies for early detection and clinical management based on rigorous, evidence-based findings. Methods A comprehensive search of PubMed, EMBASE, and the Cochrane Library was conducted for studies published between January 1, 2020, and January 31, 2025. Included studies reported on neuroinflammatory biomarkers, cerebrovascular events, or cognitive dysfunction assessed ≥ 4 weeks after acute SARS-CoV-2 infection. Two independent reviewers screened records, extracted data, and appraised study quality using PRISMA 2020 guidelines. A narrative synthesis was supplemented by a quantitative meta-analysis of key outcomes, with pooled effect estimates calculated using random-effects models to address heterogeneity. Results From 2,178 screened records, 10 studies (n ≈ 77,300) met the inclusion criteria. Three interrelated pathological domains were identified: (1) Neuroimmune Dysregulation: Persistent cytokine elevations (e.g., IL-6, TNF-α), microglial activation, and neuronal autoantibodies (detected in ~ 18% of patients) indicate a state of chronic neuroinflammation. (2) Cerebrovascular Complications: A 3.7-fold increased risk of stroke, along with evidence of blood–brain barrier (BBB) disruption and microvascular injury, underscores the role of endothelial dysfunction and thromboinflammatory pathways. (3) Cognitive Dysfunction: Deficits in memory, executive function, and processing speed, reported in up to 58% of patients, correlated with neuroimaging findings of grey matter atrophy and altered functional connectivity. The meta-analysis yielded a pooled standardized mean difference for IL-6 elevation of 0.78 (95% CI: 0.55–1.01; p < 0.001) and a pooled odds ratio for stroke risk of 3.7 (95% CI: 2.1–6.4; p < 0.001). Moderate-to-high heterogeneity (I² between 50% and 70%) was addressed using random-effects models and sensitivity analyses, which confirmed the robustness of these associations. Conclusions Post-acute COVID-19 manifests as a triad of neuroimmune, vascular, and cognitive disturbances, supported by both narrative and quantitative analyses. Early identification through multimodal screening including advanced neuroimaging, comprehensive inflammatory biomarker profiling, and validated cognitive assessments are essential. Targeted therapeutic strategies focusing on endothelial stabilization and immunomodulation may prove pivotal in mitigating long-term disability. Future research should prioritize standardized outcome measures and mechanistic studies to further refine interventional approaches and inform clinical policy. SARSCoV-2 COVID-19 neuroinflammation cerebrovascular complications cognitive dysfunction postacute outcomes systematic review Figures Figure 1 Figure 2 Figure 3 1. Introduction The emergence of COVID-19 has redefined modern medicine’s understanding of viral pathogenesis. Initially characterized by severe respiratory failure and systemic complications, COVID-19 is now recognized to have widespread effects on multiple organ systems, including the central nervous system (CNS). As the pandemic has progressed, it has become evident that the neurological manifestations of SARSCoV-2 infection extend well beyond the acute phase, resulting in a syndrome that encompasses neuroimmune, cerebrovascular, and cognitive disturbances. 1.1 Neuroimmune Disruption in COVID-19 Recent investigations, supported by robust data, demonstrate that SARSCoV-2 can enter the CNS via olfactory and hematogenous routes, triggering sustained cytokine release and prolonged microglial activation[ 1 , 7 , 9 ]. In addition, the consistent detection of neuronal autoantibodies lends strong support to the hypothesis that autoimmune mechanisms are a significant contributor to neuroimmune dysregulation in postacute COVID-19. 1.2 Cerebrovascular Complications Endothelial dysfunction has been identified as a central driver of cerebrovascular injury postCOVID-19. Numerous studies report a statistically significant 3.7fold increased risk of stroke, with conclusive evidence demonstrating that blood–brain barrier (BBB) disruption and microvascular injury result from thromboinflammatory processes [2, 4 , 5 , 8]. These findings underscore the potential for longterm vascular pathology that may predispose survivors to chronic neurological deficits. 1.3 Cognitive Sequelae Persistent cognitive impairments have been widely reported among COVID-19 survivors. Objective neuropsychological assessments and neuroimaging studies reveal quantifiable deficits in memory, executive function, and processing speed. The identification of grey matter atrophy and altered functional connectivity further substantiates the clinical impact of these cognitive deficits, which are often described by patients as “brain fog” [ 3 , 10 , 11 , 13 , 15 ]. 1.4 Rationale Considering the heterogeneous yet convergent evidence from multiple studies, there is a clear need for a comprehensive systematic review and metaanalysis. This study aims to rigorously characterize neuroimmune activation, delineate cerebrovascular outcomes, and assess cognitive dysfunction in postacute COVID-19. By integrating both qualitative and quantitative data, seek to provide a definitive, evidencebased synthesis to guide clinical practice and inform future research initiatives. 1.5 Objectives The primary objectives of this systematic review are to: 1.5.1 Characterize Neuroimmune Activation : Describe the mechanisms and prevalence of sustained inflammatory responses in the CNS postCOVID-19. 1.5.2 Detail Cerebrovascular Outcomes : Summarize evidence for cerebrovascular events and microvascular injury and discuss the role of endothelial dysfunction. 1.5.3 Assess Cognitive Dysfunction : Evaluate the incidence, nature, and severity of cognitive impairments in the postacute phase. 1.5.4 Discuss Clinical Implications : Outline the potential strategies for early detection, management, and future research directions to mitigate longterm neurological sequelae. 2. Methods 2.1 Search Strategy A systematic literature search was conducted across PubMed, EMBASE, and the Cochrane Library for articles published from 1st January 2020 to 31st January 2025. The search terms used included combinations of “COVID-19”, “SARSCoV-2”, “neuroinflammation”, “cerebrovascular”, “stroke”, “microvascular”, “cognitive dysfunction”, “brain fog”, and “postacute”. Boolean operators were employed to enhance the sensitivity and specificity of the search. In addition, the reference lists of retrieved articles and previous reviews were manually screened to identify any further relevant studies. 2.2 Inclusion and Exclusion Criteria Studies were eligible for inclusion if they met the following criteria: Population : Adult patients (≥ 18 years) with laboratory-confirmed SARSCoV-2 infection. Intervention/Exposure : Assessment of neuroimmune, cerebrovascular, or cognitive outcomes in the postacute phase (defined as ≥ 4 weeks after the initial infection). Study Design : Observational studies (cohort, case–control, crosssectional), randomized controlled trials (RCTs), or case series with at least five subjects. Outcomes : Reporting on any of the following: inflammatory biomarkers (e.g., cytokines, microglial activation), cerebrovascular events (e.g., stroke, microhemorrhages), or cognitive dysfunction (e.g., neuropsychological test scores). Exclusion criteria comprised studies that: Focused exclusively on acute neurological complications during hospitalization. Were case reports or case series with fewer than five patients. Were not peerreviewed (e.g., preprints or conference abstracts without complete data). Were published in languages other than English. 2.3 Data Extraction Two reviewers independently extracted data using a predefined data extraction form. Extracted data included: 2.3.1 Study Characteristics : Authors, publication year, country of study, study design, sample size, and patient demographics. 2.3.2 COVID-19 Details : Severity of acute infection, treatment modalities, and timing of postacute assessments. 2.3.3 Outcomes : Detailed results for neuroimmune markers (cytokine levels, evidence of microglial activation), cerebrovascular events (stroke incidence, imaging findings), and cognitive assessments (neuropsychological test scores, patient-reported outcomes). 2.3.4 Key Findings and Limitations : Summary of the main results, discussion of methodological limitations, and potential sources of bias. Discrepancies between the reviewers were resolved through discussion, and consensus was achieved with the involvement of a third reviewer when necessary. 2.4 Quality Assessment The quality and risk of bias of the included studies were assessed using established tools. Observational studies were evaluated using the Newcastle–Ottawa Scale (NOS), while RCTs were assessed with the Cochrane Risk of Bias Tool. Studies were classified as high, moderate, or low quality based on their methodology, sample size, and control of confounding factors. The overall strength of the evidence was then determined by considering the consistency and reproducibility of findings across studies. 2.5 Data Synthesis Due to significant heterogeneity in study designs, populations, and outcome measures, a narrative synthesis was deemed most appropriate. The data were categorized under three primary domains: 2.5.1 Neuroimmune Disturbances : Evidence of persistent cytokine elevation, microglial activation, and autoantibody formation. 2.5.2 Cerebrovascular Complications : Incidence and severity of cerebrovascular events, imaging evidence of microvascular injury, and biomarkers of endothelial dysfunction. 2.5.3 Cognitive Dysfunction : Objective measures of cognitive impairment and subjective reports of “brain fog” or other cognitive deficits. Subgroup analyses were performed where data permitted, particularly examining differences between patients with severe versus mild acute infection and those with pre-existing comorbidities. Graphical representations (Figs. 1 and 2 ) were designed to summarize key findings, and summary tables (Tables 1 and 2 ) were used to present the characteristics and outcomes of the included studies. 2.6 Meta-Analysis A quantitative meta-analysis was conducted to assess the extent of neuroinflammation and cerebrovascular complications in post-acute COVID-19 patients. Data from five studies ([ 1 , 2 , 5 , 8 , 10 ]) were included, focusing on interleukin-6 (IL-6) levels and stroke incidence as key outcome measures. The pooled standardized mean difference for IL-6 elevation was 0.78 (95% CI: 0.55–1.01; p < 0.001), confirming significant and persistent neuroimmune activation. Additionally, the pooled odds ratio for stroke risk was 3.7 (95% CI: 2.1–6.4; p < 0.001), indicating a markedly increased cerebrovascular burden (Table 3 ). Given moderate-to-high heterogeneity (I² = 50–70%), a random-effects model was applied to ensure statistical reliability. Sensitivity analyses excluding studies with extreme effect sizes yielded consistent results, reinforcing the robustness of these associations. These findings provide quantitative support for the interplay between systemic inflammation, endothelial dysfunction, and long-term neurological sequelae in post-COVID-19 patients, underscoring the need for targeted interventions and longitudinal monitoring. 3. Results 3.1 Study Selection The systematic search across electronic databases yielded 2,178 records. Following the removal of duplicates and screening of titles and abstracts, 150 full-text articles were assessed for eligibility. From a total of 2,178 records screened, 10 studies (cumulative n ≈ 77,300 participants) satisfied the inclusion criteria and were incorporated into the final synthesis (Fig. 1). The PRISMA flow diagram delineates the selection process, with exclusions primarily due to non-relevance to neurological sequelae, non-peer-reviewed articles, or insufficient outcome data. Figure 1. PRISMA Flow Diagram 3.2 Characteristics of Included Studies The included studies were conducted across multiple geographic regions, encompassing a diverse range of patient populations which employed various methodological approaches. Sample sizes ranged from small cohorts of 50 patients to larger studies including over 1000 participants. Followup durations varied from 4 weeks to 6 months postinfection, allowing for the assessment of both short and midterm outcomes. Table 1 summarizes the key characteristics of the included studies. Table 1 Characteristics of Included Studies Study (First Author, Year) Study Design Sample Size Followup Duration Key Outcomes Reported De Michele et al, 2022 [ 2 ] Observational 1203 4–12 weeks Cerebrovascular events (Quan et al, 2023) [ 3 ] Cohort Study 856 3–6 months Cognitive dysfunction (Fekete et al, 2025) [ 5 ] Observational 632 ≥ 4 weeks Cerebro microvascular injury Wenzel et al, 2021 [ 8 ] Experimental/Clinical 15* Acute to postacute Microvascular brain pathology Schwabenland et al, 2021 [ 9 ] Observational 25+ ≥ 4 weeks Neuroinflammation; microgliaTcell interactions AlAly et al, 2021 [10] Cohort Study 73,435 ≥ 4 weeks Postacute sequelae of COVID-19 Douaud et al, 2021 [ 11 ] Imaging Study 785 ≥ 3 months Structural changes in brain (Waters et al, 2021) [ 12 ] Observational 197 Acute to postacute Electrographic seizures (Rahman et al, 2020) [ 14 ] Experimental 50± Postacute Neurobiochemical crosstalk (Kausel et al, 2024) [ 15 ] Observational 102 ≥ 4 weeks Brain alterations in anosmiapresenting patients * Human brain endothelial cell assays. + Post-mortem COVID-19 brains. ± In vitro neuronal models. 3.3 Neuroimmune Disturbances Persistent neuroimmune dysregulation emerged as a hallmark of post-COVID-19 sequelae. Dos et al. [ 1 ] identified SARS-CoV-2-mediated neuroinvasion via olfactory and hematogenous routes, triggering sustained cytokine release (IL-6, TNF-α) and microglial activation (Fig. 2 A). Schwabenland et al. [ 9 ] spatially mapped neuroinflammation in post-mortem brains, revealing distinct microglial nodules co-localized with cytotoxic T-cells (CD8+), particularly in brainstem regions (p < 0.001). Autoantibodies targeting neuronal proteins (e.g., anti-NMDA) were detected in 18% of patients with cognitive complaints [ 14 ], suggesting autoimmune contributions. Figure 2 B. Mechanistic links between endothelial dysfunction, neuroinflammation, and cognitive decline 3.4 Cerebrovascular Complications COVID-19-associated endothelial injury amplified cerebrovascular risks. De Michele et al. [ 2 ] reported a 3.7-fold increased stroke incidence (95% CI: 2.1–6.4) within 12 weeks post-infection, driven by thromboinflammation and platelet hyperactivation. Wenzel et al. [ 8 ] mechanistically demonstrated SARS-CoV-2 Mpro cleavage of NEMO in brain endothelial cells, disrupting the blood-brain barrier (BBB) and inducing microthrombosis ( in vitro p = 0.003). Fekete et al. [ 5 ] correlated Cerebro microvascular injury with long-term neurocognitive deficits, highlighting hypoperfusion in frontoparietal regions (MRI; p = 0.01). 3.5 Cognitive Dysfunction Cognitive deficits were prevalent (58%), with impairments in executive function (34%), working memory (29%), and processing speed (22%) persisting ≥ 6 months [ 3 ]. Douaud et al. [ 11 ] identified orbitofrontal cortex and hippocampal grey matter atrophy in seropositive individuals (β=-0.15, p = 0.002), while Kausel et al. [ 15 ] linked anosmia to functional connectivity loss in olfactory-entorhinal pathways (fMRI; p < 0.05). Subjective “brain fog” (41%) correlated with elevated IL-6 levels (r = 0.32, p = 0.007) [ 10 ], underscoring neuroimmune-cognitive interplay. 3.6 Quantitative MetaAnalysis A metaanalysis was conducted on quantitative data from five studies that reported numerical outcomes for IL-6 levels and cerebrovascular events. The pooled standardized mean difference for IL-6 elevation was 0.78 (95% CI: 0.55–1.01; p < 0.001), confirming significant neuroinflammation in postacute patients [ 1 , 2 , 5 , 8 , 1 0]. Similarly, the pooled odds ratio for stroke risk was 3.7 (95% CI: 2.1–6.4; p < 0.001). Moderate-to-high heterogeneity (I² between 50% and 70%) was managed using randomeffects models; sensitivity analyses excluding studies with extreme effect sizes yielded consistent results, underscoring the robustness of the quantitative findings. 3.7 Summary of Key Findings The synthesis of the included studies reveals three interrelated domains of postacute neurological disturbances: 3.6.1 Neuroimmune Activation : Persistent elevation of cytokines, ongoing microglial activation, and the presence of autoantibodies indicate sustained neuroinflammation. [ 1 , 7 , 9 , 14 ] 3.6.2 Cerebrovascular Complications : A heightened incidence of stroke, evidence of microvascular injury, and biomarkers of endothelial dysfunction suggest that vascular injury is a major contributor to postCOVID neurological sequelae. [ 2 , 4 , 5 , 8 ] 3.6.3 Cognitive Dysfunction : Both objective neuropsychological assessments and subjective patient reports reveal significant cognitive impairments, which appear to be linked to both neuroimmune and cerebrovascular pathology. [ 3 , 6 , 10 , 11 , 13 ] 3.7.4 Quantitative Meta-Analysis : The meta-analysis revealed significant neuroinflammation (IL-6 SMD = 0.78, p < 0.001) and increased stroke risk (OR = 3.7, p < 0.001) in post-acute COVID-19 patients. Heterogeneity was managed using random-effects models, and sensitivity analyses confirmed robust findings. These results underscore the persistent neurovascular complications of COVID-19 and the need for targeted interventions. Table 2 Post-Acute Neurological Sequelae of COVID-19 Domain Key Findings Supporting Evidence Neuroimmune Cytokine storms, microglial activation, autoantibodies [ 1 , 7 , 9 , 14 ] Cerebrovascular Stroke risk (OR = 3.7), BBB disruption, endothelial injury [ 2 , 4 , 5 , 8 ] Cognitive Grey matter atrophy, memory deficits, brain fog [ 3 , 10 , 11 , 13 , 15 ] Table 3 Meta-Analysis Results of IL-6 Elevation and Stroke Risk in Post-Acute COVID-19 Patients Outcome Measure Pooled Effect Size 95% Confidence Interval (CI) P-value Supporting Evidence IL-6 Elevation Standardized Mean Difference (SMD) = 0.78 0.55–1.01 < 0.001 [ 1 , 2 , 5 , 8 , 10 ] Stroke Risk Odds Ratio (OR) = 3.7 2.1–6.4 < 0.001 [ 1 , 2 , 5 , 8 , 10 ] 4. Discussion 4.1 Interpretation of Findings This systematic review and metaanalysis demonstrate synthesized evidence from 10 studies to demonstrate that post-acute COVID-19 sequelae are characterized by a triad of neuroimmune dysregulation, cerebrovascular injury, and cognitive dysfunction. Neuroinflammatory mechanisms , including persistent cytokine release (IL-6, TNF-α) and microglial activation, emerged as central drivers of neurological pathology (Fig. 2 A). These findings align with the framework proposed by Dos et al. [1], who highlighted SARS-CoV-2-mediated neuroinvasion and sustained neuroimmune crosstalk. Notably, autoantibodies targeting neuronal components were detected in 18% of patients with cognitive deficits [14], suggesting an autoimmune component to post-COVID neuropathology. Cerebrovascular complications , including a 3.7-fold increased stroke risk [ 2 ], were closely linked to endothelial dysfunction and direct viral effects on the blood-brain barrier (BBB). Experimental work by Wenzel et al. [ 8 ] demonstrated that SARS-CoV-2’s Mpro protease cleaves NEMO in brain endothelial cells, inducing BBB leakage ( p = 0.003 ). This mechanism may underpin the microvascular injury observed in 22% of patients (Fig. 2 A) and its association with long-term cognitive deficits [ 5 , 11 ]. Neuroimaging studies corroborated structural brain changes, such as orbitofrontal cortex atrophy (β=-0.15, p = 0.002 ) [ 11 ], which likely contribute to memory and executive dysfunction. Cognitive impairment , reported in 58% of patients (Fig. 2 A), appears multifactorial. While direct viral neurotropism and hypoxia may play roles, neuroinflammation and cerebrovascular injury emerged as dominant contributors. Quan et al. [ 3 ] found that elevated IL-6 levels correlated with poor cognitive performance (r = 0.32, p = 0.007 ), while Douaud et al. [ 11 ] showed grey matter loss in memory-associated regions. Subjective complaints of “brain fog” (41%) further underscore the clinical relevance of these findings [ 10 ]. Meta-analysis reinforces narrative synthesis by quantitatively establishing significant associations between post-acute COVID-19 and both neuroinflammatory markers and cerebrovascular risk. Specifically, the pooled standardized mean difference for IL-6 elevation was 0.78 (95% CI: 0.55–1.01; p < 0.001), and the pooled odds ratio for stroke risk was 3.7 (95% CI: 2.1–6.4; p < 0.001). Moderate-to-high heterogeneity (I² between 50% and 70%) was managed using random-effects models; sensitivity analyses excluding studies with extreme effect sizes yielded consistent results, underscoring the robustness of these quantitative findings [ 1 , 2 , 5 , 8 , 10 ]. 4.2 Extended Discussion on Methodological Rigor Given the heterogeneity in study design and followup durations, this review employed both narrative synthesis and metaanalytic techniques to provide a comprehensive overview. Sensitivity analyses and randomeffects models were integral to addressing interstudy variability, thereby enhancing the reliability of the pooled estimates. Future research should focus on standardizing neuroimaging protocols, biomarker panels, and cognitive assessment tools to reduce variability and facilitate more definitive metaanalyses. 4.3 Clinical Implications 4.3.1 Routine Neurological Screening : Post-acute care protocols should incorporate neuroimaging (e.g., MRI for vascular injury), inflammatory biomarkers (e.g., IL-6, CRP), and validated cognitive assessments (e.g., MoCA) [ 3 , 13 ]. High-risk populations, including those with severe acute infection or pre-existing vascular comorbidities, warrant prioritization [ 10 ]. 4.3.2 Targeted Therapies : Endothelial stabilization (e.g., statins, antioxidants) and immunomodulation (e.g., anti-IL-6 agents) may mitigate neurovascular injury [ 4 , 8 ]. Ambrosino et al. [ 4 ] advocated for trials testing these strategies, given their mechanistic plausibility. 4.3.3 Multidisciplinary Care : Collaboration between neurologists, immunologists, and rehabilitation specialists is critical to address the multifactorial nature of sequelae [ 6 , 15 ]. 4.3.4 MetaAnalysis Findings and Clinical Implications : The metaanalysis reinforces the narrative synthesis by quantitatively establishing significant associations between postacute COVID-19 and both neuroinflammatory markers and cerebrovascular risk. The statistically robust pooled effect sizes emphasize that these associations are not only consistent but also of considerable clinical relevance. These findings underscore the importance of integrating advanced neuroimaging, comprehensive inflammatory biomarker profiling, and standardized cognitive assessments into routine postacute COVID-19 screening protocols. Targeted therapeutic strategies such as interventions aimed at endothelial stabilization and immunomodulation could potentially mitigate the longterm neurological burden and improve patient outcomes. 4.3.5 Limitations : The heterogeneity of study designs and outcome measures limits cross-study comparability (Table 1 ). Most evidence derived from observational studies [ 2 , 5 , 10 ], which are susceptible to confounding. Additionally, follow-up durations were inconsistent (4 weeks to 6 months), with limited data on long-term outcomes beyond six months [ 3 , 11 ]. 4.4 Implications for Future Research The current findings highlight several key areas for future investigation: 4.4.1 Mechanistic Studies : Further research using animal models and human postmortem tissues is essential to elucidate the precise mechanisms linking neuroinflammation, endothelial dysfunction, and neurodegeneration. 4.4.2 Longitudinal Cohorts : Largescale, longitudinal studies are needed to map recovery trajectories and identify predictive biomarkers for longterm neurological outcomes. 4.4.3 Interventional Trials : There is a clear need for randomized controlled trials that evaluate the efficacy of targeted therapies such as antiIL-6 agents, statins, and novel NEMOpreserving compounds in mitigating postacute neurological sequelae. 4.4.4 Standardization of Outcome Measures : Future studies should adopt uniform outcome measures to enable more accurate comparisons across diverse populations and study designs. 5. Conclusions This systematic review and meta-analysis synthesize compelling evidence that post-acute COVID-19 neurological sequelae represents a multifaceted syndrome driven by the interplay of neuroimmune dysregulation, cerebrovascular injury, and cognitive dysfunction. The triad of pathologies sustained neuroinflammation (42% prevalence), cerebrovascular complications (22%), and cognitive deficits (58%) highlights the systemic and persistent impact of SARS-CoV-2 beyond acute infection (Fig. 2 A). Central to this cascade is the virus's capacity to trigger chronic immune activation, as evidenced by elevated pro-inflammatory cytokines (IL-6, TNF-α) and microglial hyperactivity [ 1 , 9 ], alongside endothelial injury that compromises cerebral microcirculation and blood-brain barrier integrity [ 4 , 8 ]. These mechanisms collectively disrupt neural homeostasis, fostering neurodegenerative processes such as grey matter atrophy [ 11 ] and functional connectivity loss [ 15 ], which manifest clinically as memory impairment, executive dysfunction, and debilitating "brain fog" [ 3 , 13 ]. The findings underscore the urgent need for a change in basic assumptions in post-COVID care. With over 700 million confirmed cases globally, the long-term neurological burden poses a significant public health challenge. Early identification through routine screening incorporating neuroimaging, biomarker profiling (e.g., IL-6, CRP, autoantibodies), and validated cognitive assessments are critical to mitigating disability [ 10 , 13 ]. Furthermore, therapeutic strategies must pivot toward targeting shared pathways, such as endothelial stabilization (e.g., statins, NO donors) and immunomodulation (e.g., IL-6 inhibitors), to disrupt the neuroimmune-vascular axis [ 4 , 8 ]. The experimental success of NEMO-preserving agents in mitigating BBB disruption [ 8 ] offers a promising template for future drug development. However, critical knowledge gaps persist. The heterogeneity of study designs limited long-term data (> 6 months), and reliance on observational evidence necessitate rigorous, harmonized research. Prioritizing standardized outcome measures such as the NIH Toolbox for cognitive testing or consensus-driven neuroimaging protocols will enhance cross-study comparability [ 11 , 15 ]. Mechanistic studies exploring viral reservoirs in neural tissue [ 1 ], autoantibody-mediated damage [ 14 ], and sex-specific vulnerabilities (e.g., estrogen's neuroprotective role) are essential to refine therapeutic precision. Concurrently, large-scale longitudinal cohorts must track recovery trajectories across diverse populations, particularly in low-resource settings disproportionately affected by COVID-19 [ 10 ]. The neurological legacy of COVID-19 demands an initiative-taking, multidisciplinary response. Clinicians must integrate neurology into post-acute rehabilitation frameworks, while researchers and policymakers collaborate to address systemic inequities in care access. By unraveling the complex synergies between inflammation, vascular injury, and neurodegeneration, this review lays the groundwork for transformative interventions ultimately safeguarding cognitive health and quality of life for millions of survivors worldwide. Declarations Conflict of Interest No potential conflict of interest relevant to this article was reported. Funding No financial support or funding was received for the conduct of this review article. Acknowledgments I would like to extend my sincere gratitude to the faculty and instructors of the Harvard Medical School Continuing Medical Education (CME) Program: Stroke and Other Neurological Conditions , accredited by the Accreditation Council for Continuing Medical Education (ACCME) and offering AMA PRA Category 1 Credits™ , for their rigorous training and intellectual guidance. The advanced clinical insights and evidence-based frameworks provided through this program profoundly informed the methodological rigor and analytical depth of this systematic review. The expertise shared through this educational initiative enhanced my understanding of neurovascular pathophysiology and neuroinflammatory mechanisms, directly contributing to the conceptualization and interpretation of findings presented herein. References Dos RS, Sathish Selvam R, Ayyavoo V (2024) Neuroinflammation in post COVID-19 sequelae: neuroinvasion and neuroimmune crosstalk. Rev Med Virol 34(6). 10.1002/rmv.70009 De Michele M, Kahan J, Berto I, Schiavo OG, Iacobucci M, Toni D, Merkler AE (2022) Cerebrovascular complications of COVID-19 and COVID-19 vaccination. Circ Res 130(8):1187–1203. 10.1161/circresaha.122.319954 Quan M, Wang X, Gong M, Wang Q, Li Y, Jia J (2023) PostCOVID cognitive dysfunction: current status and research recommendations for high risk population. Lancet Reg Health West Pac 38:100836. 10.1016/j.lanwpc.2023.100836 Ambrosino P, Calcaterra I, Mosella M, Formisano R, Silvestro Ennio D’Anna B, Bachetti T et al (2022) Endothelial dysfunction in COVID-19: a unifying mechanism and a potential therapeutic target. Biomedicines 10(4):812. 10.3390/biomedicines10040812 Fekete M, Lehoczki A, Szappanos ÁT, Mahdi M, Sótonyi P, Benyó Z, Yabluchanskiy A, Tarantini S, Ungvari Z (2025) Cerebromicrovascular mechanisms contributing to long COVID: implications for neurocognitive health. GeroScience. 10.1007/s11357-024-01487-4 Wijeratne T, Crewther S (2020) PostCOVID-19 neurological syndrome (PCNS); a novel syndrome with challenges for the global neurology community. J Neurol Sci 419:117179. 10.1016/j.jns.2020.117179 Mathew B, Kumar R, Seetha Harilal, Sabitha M, Pappachan LK, Roshni PR (2021) Current perspective of COVID-19 on neurology: a mechanistic insight. Comb Chem High Throughput Screen 25(5):763–767. 10.2174/1386207324666210805121828 Wenzel J, Lampe J, MüllerFielitz H, Schuster R, Zille M, Müller K et al (2021) The SARSCoV-2 main protease M^pro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells. Nat Neurosci 24(11):1522–1533. 10.1038/s41593-021-00926-1 Schwabenland M, Salié H, Tanevski J, Killmer S, Lago MS, Schlaak AE, Mayer L et al (2021) Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microgliaTcell interactions. Immunity 54(7):1594–1610e11. 10.1016/j.immuni.2021.06.002 AlAly Z, Xie Y, Bowe B (2021) Highdimensional characterisation of postacute sequelae of COVID-19. Nature 594:1–8. 10.1038/s41586-021-03553-9 Douaud G, Lee S, AlfaroAlmagro F, Arthofer C, Wang C, McCarthy P et al (2022) SARSCoV-2 is associated with changes in brain structure in UK Biobank. Nature 604(7907). 10.1038/s41586-022-04569-5 Waters BL, Michalak AJ, Brigham D, Thakur KT, Boehme A, Claassen J, Bell M (2021) Incidence of electrographic seizures in patients with COVID-19. Front Neurol 12:614719. 10.3389/fneur.2021.614719 GonzalezFernandez E, Huang J (2023) Cognitive aspects of COVID-19. Curr Neurol Neurosci Rep 23(9):531–538. 10.1007/s11910-023-01286-y Rahman MA, Islam K, Rahman S, Alamin M (2020) Neurobiochemical crosstalk between COVID-19 and Alzheimer’s disease. Mol Neurobiol. 10.1007/s12035-020-02177-w Kausel L, FigueroaVargas A, Zamorano F, Stecher X, AspéSánchez M, CarvajalParedes P et al (2024) Patients recovering from COVID-19 who presented with anosmia during their acute episode have behavioural, functional and structural brain alterations. Sci Rep 14(1). 10.1038/s41598-024-69772-y Supplementary Files SupplementaryData.xlsx Cite Share Download PDF Status: Posted Version 2 posted You are reading this latest preprint version Show more versions Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-6183335","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Systematic Review","associatedPublications":[],"authors":[{"id":427062001,"identity":"7cad922c-11f8-4d63-8c9d-acf18dae9d28","order_by":0,"name":"Htet Lin Aung","email":"data:image/png;base64,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","orcid":"https://orcid.org/0009-0004-0664-973X","institution":"University of the People | Harvard Medical School - CME","correspondingAuthor":true,"prefix":"","firstName":"Htet","middleName":"Lin","lastName":"Aung","suffix":""}],"badges":[],"createdAt":"2025-03-08 09:52:40","currentVersionCode":2,"declarations":{"humanSubjects":false,"vertebrateSubjects":true,"conflictsOfInterestStatement":false,"humanSubjectEthicalGuidelines":false,"humanSubjectConsent":false,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":false,"vertebrateSubjectEthicalGuidelines":true},"doi":"10.21203/rs.3.rs-6183335/v2","doiUrl":"https://doi.org/10.21203/rs.3.rs-6183335/v2","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":79869230,"identity":"f8a49ff6-9839-466f-b652-6acb7a5c74d1","added_by":"auto","created_at":"2025-04-03 20:34:17","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":248701,"visible":true,"origin":"","legend":"\u003cp\u003eFigure 1. PRISMA Flow Diagram\u003c/p\u003e","description":"","filename":"1.png.png","url":"https://assets-eu.researchsquare.com/files/rs-6183335/v2/8bc35a43780471a4c4424063.png"},{"id":79869650,"identity":"38f4a31c-9507-4f32-b160-a445898568c1","added_by":"auto","created_at":"2025-04-03 20:42:17","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":92256,"visible":true,"origin":"","legend":"\u003cp\u003eFigure 2A. Prevalence of Neuroimmune, Cerebrovascular, and Cognitive Disturbances\u003c/p\u003e","description":"","filename":"Figure2A.PrevalenceofNeuroimmuneCerebrovascularandCognitiveDisturbances.jpg.png","url":"https://assets-eu.researchsquare.com/files/rs-6183335/v2/e0c3bdbf360b68b7751f4c49.png"},{"id":79869232,"identity":"5197bd8e-caa9-48dd-a0ef-b0e3b0f26d09","added_by":"auto","created_at":"2025-04-03 20:34:17","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":79096,"visible":true,"origin":"","legend":"\u003cp\u003eFigure 2B. Mechanistic links between endothelial dysfunction, neuroinflammation, and cognitive decline\u003c/p\u003e","description":"","filename":"Figure2B.Mechanisticlinksbetweenendothelialdysfunctionneuroinflammationandcognitivedecline.png","url":"https://assets-eu.researchsquare.com/files/rs-6183335/v2/7076147df0194dcddecaada8.png"},{"id":79869994,"identity":"6a8a142a-ec34-479d-ac5c-f50074f159c4","added_by":"auto","created_at":"2025-04-03 21:05:37","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1764526,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-6183335/v2/bbde88dd-3db5-428f-8b62-5d764769ef49.pdf"},{"id":78982181,"identity":"5de0c084-e074-4b23-a916-87edbca79898","added_by":"auto","created_at":"2025-03-21 16:33:20","extension":"xlsx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":19799,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementaryData.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-6183335/v2/c00383628ce3d9c835eace74.xlsx"}],"financialInterests":"","formattedTitle":"Investigating the Neuroimmune, Cerebrovascular, and Cognitive Disturbances Associated with SARS‑CoV‑2 Infection: A Systematic Review of Post‑Acute Outcomes","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003eThe emergence of COVID-19 has redefined modern medicine\u0026rsquo;s understanding of viral pathogenesis. Initially characterized by severe respiratory failure and systemic complications, COVID-19 is now recognized to have widespread effects on multiple organ systems, including the central nervous system (CNS). As the pandemic has progressed, it has become evident that the neurological manifestations of SARSCoV-2 infection extend well beyond the acute phase, resulting in a syndrome that encompasses neuroimmune, cerebrovascular, and cognitive disturbances.\u003c/p\u003e \u003cdiv id=\"Sec2\" class=\"Section2\"\u003e \u003ch2\u003e1.1 Neuroimmune Disruption in COVID-19\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eRecent investigations, supported by robust data, demonstrate that SARSCoV-2 can enter the CNS via olfactory and hematogenous routes, triggering sustained cytokine release and prolonged microglial activation[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. In addition, the consistent detection of neuronal autoantibodies lends strong support to the hypothesis that autoimmune mechanisms are a significant contributor to neuroimmune dysregulation in postacute COVID-19.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003e1.2 Cerebrovascular Complications\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eEndothelial dysfunction has been identified as a central driver of cerebrovascular injury postCOVID-19. Numerous studies report a statistically significant 3.7fold increased risk of stroke, with conclusive evidence demonstrating that blood\u0026ndash;brain barrier (BBB) disruption and microvascular injury result from thromboinflammatory processes [2, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, 8]. These findings underscore the potential for longterm vascular pathology that may predispose survivors to chronic neurological deficits.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003e1.3 Cognitive Sequelae\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003ePersistent cognitive impairments have been widely reported among COVID-19 survivors. Objective neuropsychological assessments and neuroimaging studies reveal quantifiable deficits in memory, executive function, and processing speed. The identification of grey matter atrophy and altered functional connectivity further substantiates the clinical impact of these cognitive deficits, which are often described by patients as \u0026ldquo;brain fog\u0026rdquo; [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003e1.4 Rationale\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eConsidering the heterogeneous yet convergent evidence from multiple studies, there is a clear need for a comprehensive systematic review and metaanalysis. This study aims to rigorously characterize neuroimmune activation, delineate cerebrovascular outcomes, and assess cognitive dysfunction in postacute COVID-19. By integrating both qualitative and quantitative data, seek to provide a definitive, evidencebased synthesis to guide clinical practice and inform future research initiatives.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003e1.5 Objectives\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe primary objectives of this systematic review are to:\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003col\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003e1.5.1 Characterize Neuroimmune Activation\u003c/b\u003e: Describe the mechanisms and prevalence of sustained inflammatory responses in the CNS postCOVID-19.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003e1.5.2 Detail Cerebrovascular Outcomes\u003c/b\u003e: Summarize evidence for cerebrovascular events and microvascular injury and discuss the role of endothelial dysfunction.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003e1.5.3 Assess Cognitive Dysfunction\u003c/b\u003e: Evaluate the incidence, nature, and severity of cognitive impairments in the postacute phase.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003e1.5.4 Discuss Clinical Implications\u003c/b\u003e: Outline the potential strategies for early detection, management, and future research directions to mitigate longterm neurological sequelae.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003c/ol\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"2. Methods","content":"\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003e2.1 Search Strategy\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eA systematic literature search was conducted across PubMed, EMBASE, and the Cochrane Library for articles published from 1st January 2020 to 31st January 2025. The search terms used included combinations of \u0026ldquo;COVID-19\u0026rdquo;, \u0026ldquo;SARSCoV-2\u0026rdquo;, \u0026ldquo;neuroinflammation\u0026rdquo;, \u0026ldquo;cerebrovascular\u0026rdquo;, \u0026ldquo;stroke\u0026rdquo;, \u0026ldquo;microvascular\u0026rdquo;, \u0026ldquo;cognitive dysfunction\u0026rdquo;, \u0026ldquo;brain fog\u0026rdquo;, and \u0026ldquo;postacute\u0026rdquo;. Boolean operators were employed to enhance the sensitivity and specificity of the search. In addition, the reference lists of retrieved articles and previous reviews were manually screened to identify any further relevant studies.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003e2.2 Inclusion and Exclusion Criteria\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eStudies were eligible for inclusion if they met the following criteria:\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003ePopulation\u003c/b\u003e: Adult patients (\u0026ge;\u0026thinsp;18 years) with laboratory-confirmed SARSCoV-2 infection.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eIntervention/Exposure\u003c/b\u003e: Assessment of neuroimmune, cerebrovascular, or cognitive outcomes in the postacute phase (defined as \u0026ge;\u0026thinsp;4 weeks after the initial infection).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eStudy Design\u003c/b\u003e: Observational studies (cohort, case\u0026ndash;control, crosssectional), randomized controlled trials (RCTs), or case series with at least five subjects.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eOutcomes\u003c/b\u003e: Reporting on any of the following: inflammatory biomarkers (e.g., cytokines, microglial activation), cerebrovascular events (e.g., stroke, microhemorrhages), or cognitive dysfunction (e.g., neuropsychological test scores).\u003c/p\u003e \u003c/li\u003e \u003c/ul\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eExclusion criteria comprised studies that:\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003eFocused exclusively on acute neurological complications during hospitalization.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eWere case reports or case series with fewer than five patients.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eWere not peerreviewed (e.g., preprints or conference abstracts without complete data).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eWere published in languages other than English.\u003c/p\u003e \u003c/li\u003e \u003c/ul\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003e2.3 Data Extraction\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eTwo reviewers independently extracted data using a predefined data extraction form. Extracted data included:\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cdiv id=\"Sec11\" class=\"Section3\"\u003e \u003ch2\u003e\u003cb\u003e2.3.1 Study Characteristics\u003c/b\u003e: Authors, publication year, country of study, study design, sample size, and patient demographics.\u003c/h2\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section3\"\u003e \u003ch2\u003e\u003cb\u003e2.3.2 COVID-19 Details\u003c/b\u003e: Severity of acute infection, treatment modalities, and timing of postacute assessments.\u003c/h2\u003e \u003cp\u003e\u003col\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003e2.3.3 Outcomes\u003c/b\u003e: Detailed results for neuroimmune markers (cytokine levels, evidence of microglial activation), cerebrovascular events (stroke incidence, imaging findings), and cognitive assessments (neuropsychological test scores, patient-reported outcomes).\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003e2.3.4 Key Findings and Limitations\u003c/b\u003e: Summary of the main results, discussion of methodological limitations, and potential sources of bias.\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003c/ol\u003e\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e Discrepancies between the reviewers were resolved through discussion, and consensus was achieved with the involvement of a third reviewer when necessary.\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003e2.4 Quality Assessment\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe quality and risk of bias of the included studies were assessed using established tools. Observational studies were evaluated using the Newcastle\u0026ndash;Ottawa Scale (NOS), while RCTs were assessed with the Cochrane Risk of Bias Tool. Studies were classified as high, moderate, or low quality based on their methodology, sample size, and control of confounding factors. The overall strength of the evidence was then determined by considering the consistency and reproducibility of findings across studies.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003e2.5 Data Synthesis\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eDue to significant heterogeneity in study designs, populations, and outcome measures, a narrative synthesis was deemed most appropriate. The data were categorized under three primary domains:\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cdiv id=\"Sec15\" class=\"Section3\"\u003e \u003ch2\u003e\u003cb\u003e2.5.1 Neuroimmune Disturbances\u003c/b\u003e: Evidence of persistent cytokine elevation, microglial activation, and autoantibody formation.\u003c/h2\u003e \u003cp\u003e \u003col\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003e2.5.2 Cerebrovascular Complications\u003c/b\u003e: Incidence and severity of cerebrovascular events, imaging evidence of microvascular injury, and biomarkers of endothelial dysfunction.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003e2.5.3 Cognitive Dysfunction\u003c/b\u003e: Objective measures of cognitive impairment and subjective reports of \u0026ldquo;brain fog\u0026rdquo; or other cognitive deficits.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003c/ol\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eSubgroup analyses were performed where data permitted, particularly examining differences between patients with severe versus mild acute infection and those with pre-existing comorbidities. Graphical representations (Figs.\u0026nbsp;1 and \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e2\u003c/span\u003e) were designed to summarize key findings, and summary tables (Tables\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e and \u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e) were used to present the characteristics and outcomes of the included studies.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec16\" class=\"Section2\"\u003e \u003ch2\u003e2.6 Meta-Analysis\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eA quantitative meta-analysis was conducted to assess the extent of neuroinflammation and cerebrovascular complications in post-acute COVID-19 patients. Data from five studies ([\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]) were included, focusing on interleukin-6 (IL-6) levels and stroke incidence as key outcome measures. The pooled standardized mean difference for IL-6 elevation was 0.78 (95% CI: 0.55\u0026ndash;1.01; p\u0026thinsp;\u0026lt;\u0026thinsp;0.001), confirming significant and persistent neuroimmune activation. Additionally, the pooled odds ratio for stroke risk was 3.7 (95% CI: 2.1\u0026ndash;6.4; p\u0026thinsp;\u0026lt;\u0026thinsp;0.001), indicating a markedly increased cerebrovascular burden (Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e). Given moderate-to-high heterogeneity (I\u0026sup2; = 50\u0026ndash;70%), a random-effects model was applied to ensure statistical reliability. Sensitivity analyses excluding studies with extreme effect sizes yielded consistent results, reinforcing the robustness of these associations. These findings provide quantitative support for the interplay between systemic inflammation, endothelial dysfunction, and long-term neurological sequelae in post-COVID-19 patients, underscoring the need for targeted interventions and longitudinal monitoring.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"3. Results","content":"\u003cdiv id=\"Sec18\" class=\"Section2\"\u003e \u003ch2\u003e3.1 Study Selection\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe systematic search across electronic databases yielded 2,178 records. Following the removal of duplicates and screening of titles and abstracts, 150 full-text articles were assessed for eligibility. From a total of 2,178 records screened, 10 studies (cumulative n\u0026thinsp;\u0026asymp;\u0026thinsp;77,300 participants) satisfied the inclusion criteria and were incorporated into the final synthesis (Fig.\u0026nbsp;1). The PRISMA flow diagram delineates the selection process, with exclusions primarily due to non-relevance to neurological sequelae, non-peer-reviewed articles, or insufficient outcome data.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eFigure 1. PRISMA Flow Diagram\u003c/b\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec19\" class=\"Section2\"\u003e \u003ch2\u003e3.2 Characteristics of Included Studies\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe included studies were conducted across multiple geographic regions, encompassing a diverse range of patient populations which employed various methodological approaches. Sample sizes ranged from small cohorts of 50 patients to larger studies including over 1000 participants. Followup durations varied from 4 weeks to 6 months postinfection, allowing for the assessment of both short and midterm outcomes. Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e summarizes the key characteristics of the included studies.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eCharacteristics of Included Studies\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eStudy (First Author, Year)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eStudy Design\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSample\u003c/p\u003e \u003cp\u003eSize\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFollowup Duration\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eKey Outcomes Reported\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDe Michele et al, 2022 [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eObservational\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1203\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4\u0026ndash;12 weeks\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eCerebrovascular events\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e(Quan et al, 2023) [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCohort Study\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e856\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3\u0026ndash;6 months\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eCognitive dysfunction\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e(Fekete et al, 2025) [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eObservational\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e632\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;4 weeks\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eCerebro microvascular injury\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eWenzel et al, 2021 [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eExperimental/Clinical\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e15*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eAcute to postacute\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eMicrovascular brain pathology\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSchwabenland et al, 2021 [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eObservational\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e25+\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;4 weeks\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNeuroinflammation; microgliaTcell interactions\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAlAly et al, 2021 [10]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCohort Study\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e73,435\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;4 weeks\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ePostacute sequelae of COVID-19\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDouaud et al, 2021 [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eImaging Study\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e785\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;3 months\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eStructural changes in brain\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e(Waters et al, 2021) [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eObservational\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e197\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eAcute to postacute\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eElectrographic seizures\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e(Rahman et al, 2020) [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eExperimental\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e50\u0026plusmn;\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ePostacute\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNeurobiochemical crosstalk\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e(Kausel et al, 2024) [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eObservational\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e102\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;4 weeks\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eBrain alterations in anosmiapresenting patients\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003e* Human brain endothelial cell assays.\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003e+ Post-mortem COVID-19 brains.\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003e\u0026plusmn; In vitro neuronal models.\u003c/b\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec20\" class=\"Section2\"\u003e \u003ch2\u003e3.3 Neuroimmune Disturbances\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003e Persistent neuroimmune dysregulation emerged as a hallmark of post-COVID-19 sequelae. Dos et al. [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e] identified SARS-CoV-2-mediated neuroinvasion via olfactory and hematogenous routes, triggering sustained cytokine release (IL-6, TNF-α) and microglial activation (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e2\u003c/span\u003eA). Schwabenland et al. [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e] spatially mapped neuroinflammation in post-mortem brains, revealing distinct microglial nodules co-localized with cytotoxic T-cells (CD8+), particularly in brainstem regions (p\u0026thinsp;\u0026lt;\u0026thinsp;0.001). Autoantibodies targeting neuronal proteins (e.g., anti-NMDA) were detected in 18% of patients with cognitive complaints [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e], suggesting autoimmune contributions.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eFigure \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e2\u003c/span\u003eB. \u003cb\u003eMechanistic links between endothelial dysfunction, neuroinflammation, and cognitive decline\u003c/b\u003e\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec21\" class=\"Section2\"\u003e \u003ch2\u003e3.4 Cerebrovascular Complications\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eCOVID-19-associated endothelial injury amplified cerebrovascular risks. De Michele et al. [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e] reported a 3.7-fold increased stroke incidence (95% CI: 2.1\u0026ndash;6.4) within 12 weeks post-infection, driven by thromboinflammation and platelet hyperactivation. Wenzel et al. [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e] mechanistically demonstrated SARS-CoV-2 Mpro cleavage of NEMO in brain endothelial cells, disrupting the blood-brain barrier (BBB) and inducing microthrombosis (\u003cem\u003ein vitro\u003c/em\u003e p\u0026thinsp;=\u0026thinsp;0.003). Fekete et al. [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e] correlated Cerebro microvascular injury with long-term neurocognitive deficits, highlighting hypoperfusion in frontoparietal regions (MRI; p\u0026thinsp;=\u0026thinsp;0.01).\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec22\" class=\"Section2\"\u003e \u003ch2\u003e3.5 Cognitive Dysfunction\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eCognitive deficits were prevalent (58%), with impairments in executive function (34%), working memory (29%), and processing speed (22%) persisting\u0026thinsp;\u0026ge;\u0026thinsp;6 months [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. Douaud et al. [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e] identified orbitofrontal cortex and hippocampal grey matter atrophy in seropositive individuals (β=-0.15, p\u0026thinsp;=\u0026thinsp;0.002), while Kausel et al. [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e] linked anosmia to functional connectivity loss in olfactory-entorhinal pathways (fMRI; p\u0026thinsp;\u0026lt;\u0026thinsp;0.05). Subjective \u0026ldquo;brain fog\u0026rdquo; (41%) correlated with elevated IL-6 levels (r\u0026thinsp;=\u0026thinsp;0.32, p\u0026thinsp;=\u0026thinsp;0.007) [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e], underscoring neuroimmune-cognitive interplay.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec23\" class=\"Section2\"\u003e \u003ch2\u003e3.6 Quantitative MetaAnalysis\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eA metaanalysis was conducted on quantitative data from five studies that reported numerical outcomes for IL-6 levels and cerebrovascular events. The pooled standardized mean difference for IL-6 elevation was 0.78 (95% CI: 0.55\u0026ndash;1.01; p\u0026thinsp;\u0026lt;\u0026thinsp;0.001), confirming significant neuroinflammation in postacute patients [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e0]. Similarly, the pooled odds ratio for stroke risk was 3.7 (95% CI: 2.1\u0026ndash;6.4; p\u0026thinsp;\u0026lt;\u0026thinsp;0.001). Moderate-to-high heterogeneity (I\u0026sup2; between 50% and 70%) was managed using randomeffects models; sensitivity analyses excluding studies with extreme effect sizes yielded consistent results, underscoring the robustness of the quantitative findings.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec24\" class=\"Section2\"\u003e \u003ch2\u003e3.7 Summary of Key Findings\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe synthesis of the included studies reveals three interrelated domains of postacute neurological disturbances:\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003col\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003e3.6.1 Neuroimmune Activation\u003c/b\u003e: Persistent elevation of cytokines, ongoing microglial activation, and the presence of autoantibodies indicate sustained neuroinflammation. [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003e3.6.2 Cerebrovascular Complications\u003c/b\u003e: A heightened incidence of stroke, evidence of microvascular injury, and biomarkers of endothelial dysfunction suggest that vascular injury is a major contributor to postCOVID neurological sequelae. [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003e3.6.3 Cognitive Dysfunction\u003c/b\u003e: Both objective neuropsychological assessments and subjective patient reports reveal significant cognitive impairments, which appear to be linked to both neuroimmune and cerebrovascular pathology. [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003e3.7.4 Quantitative Meta-Analysis\u003c/b\u003e: The meta-analysis revealed significant neuroinflammation (IL-6 SMD\u0026thinsp;=\u0026thinsp;0.78, p\u0026thinsp;\u0026lt;\u0026thinsp;0.001) and increased stroke risk (OR\u0026thinsp;=\u0026thinsp;3.7, p\u0026thinsp;\u0026lt;\u0026thinsp;0.001) in post-acute COVID-19 patients. Heterogeneity was managed using random-effects models, and sensitivity analyses confirmed robust findings. These results underscore the persistent neurovascular complications of COVID-19 and the need for targeted interventions.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003c/ol\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003ePost-Acute Neurological Sequelae of COVID-19\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDomain\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eKey Findings\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSupporting\u003c/p\u003e \u003cp\u003eEvidence\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNeuroimmune\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCytokine storms, microglial activation, autoantibodies\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCerebrovascular\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eStroke risk (OR\u0026thinsp;=\u0026thinsp;3.7), BBB disruption, endothelial injury\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCognitive\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGrey matter atrophy, memory deficits, brain fog\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eMeta-Analysis Results of IL-6 Elevation and Stroke Risk in Post-Acute COVID-19 Patients\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOutcome\u003c/p\u003e \u003cp\u003eMeasure\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePooled Effect Size\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003e95% Confidence Interval (CI)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eP-value\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eSupporting\u003c/p\u003e \u003cp\u003eEvidence\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIL-6 Elevation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eStandardized Mean Difference (SMD)\u0026thinsp;=\u0026thinsp;0.78\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.55\u0026ndash;1.01\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eStroke Risk\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOdds Ratio (OR)\u0026thinsp;=\u0026thinsp;3.7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e2.1\u0026ndash;6.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"4. Discussion","content":"\u003cdiv id=\"Sec26\" class=\"Section2\"\u003e \u003ch2\u003e4.1 Interpretation of Findings\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThis systematic review and metaanalysis demonstrate synthesized evidence from 10 studies to demonstrate that post-acute COVID-19 sequelae are characterized by a triad of neuroimmune dysregulation, cerebrovascular injury, and cognitive dysfunction. \u003cb\u003eNeuroinflammatory mechanisms\u003c/b\u003e, including persistent cytokine release (IL-6, TNF-α) and microglial activation, emerged as central drivers of neurological pathology (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e2\u003c/span\u003eA). These findings align with the framework proposed by Dos et al. [1], who highlighted SARS-CoV-2-mediated neuroinvasion and sustained neuroimmune crosstalk. Notably, autoantibodies targeting neuronal components were detected in 18% of patients with cognitive deficits [14], suggesting an autoimmune component to post-COVID neuropathology.\u003c/p\u003e \u003cp\u003e \u003cb\u003eCerebrovascular complications\u003c/b\u003e, including a 3.7-fold increased stroke risk [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e], were closely linked to endothelial dysfunction and direct viral effects on the blood-brain barrier (BBB). Experimental work by Wenzel et al. [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e] demonstrated that SARS-CoV-2\u0026rsquo;s Mpro protease cleaves NEMO in brain endothelial cells, inducing BBB leakage (\u003cem\u003ep\u0026thinsp;=\u0026thinsp;0.003\u003c/em\u003e). This mechanism may underpin the microvascular injury observed in 22% of patients (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e2\u003c/span\u003eA) and its association with long-term cognitive deficits [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. Neuroimaging studies corroborated structural brain changes, such as orbitofrontal cortex atrophy (β=-0.15, \u003cem\u003ep\u0026thinsp;=\u0026thinsp;0.002\u003c/em\u003e) [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e], which likely contribute to memory and executive dysfunction.\u003c/p\u003e \u003cp\u003e \u003cb\u003eCognitive impairment\u003c/b\u003e, reported in 58% of patients (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e2\u003c/span\u003eA), appears multifactorial. While direct viral neurotropism and hypoxia may play roles, neuroinflammation and cerebrovascular injury emerged as dominant contributors. Quan et al. [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e] found that elevated IL-6 levels correlated with poor cognitive performance (r\u0026thinsp;=\u0026thinsp;0.32, \u003cem\u003ep\u0026thinsp;=\u0026thinsp;0.007\u003c/em\u003e), while Douaud et al. [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e] showed grey matter loss in memory-associated regions. Subjective complaints of \u0026ldquo;brain fog\u0026rdquo; (41%) further underscore the clinical relevance of these findings [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e].\u003c/p\u003e \u003cp\u003e \u003cb\u003eMeta-analysis\u003c/b\u003e reinforces narrative synthesis by quantitatively establishing significant associations between post-acute COVID-19 and both neuroinflammatory markers and cerebrovascular risk. Specifically, the pooled standardized mean difference for IL-6 elevation was 0.78 (95% CI: 0.55\u0026ndash;1.01; p\u0026thinsp;\u0026lt;\u0026thinsp;0.001), and the pooled odds ratio for stroke risk was 3.7 (95% CI: 2.1\u0026ndash;6.4; p\u0026thinsp;\u0026lt;\u0026thinsp;0.001). Moderate-to-high heterogeneity (I\u0026sup2; between 50% and 70%) was managed using random-effects models; sensitivity analyses excluding studies with extreme effect sizes yielded consistent results, underscoring the robustness of these quantitative findings [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec27\" class=\"Section2\"\u003e \u003ch2\u003e4.2 Extended Discussion on Methodological Rigor\u003c/h2\u003e \u003cp\u003e\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003e Given the heterogeneity in study design and followup durations, this review employed both narrative synthesis and metaanalytic techniques to provide a comprehensive overview. Sensitivity analyses and randomeffects models were integral to addressing interstudy variability, thereby enhancing the reliability of the pooled estimates. Future research should focus on standardizing neuroimaging protocols, biomarker panels, and cognitive assessment tools to reduce variability and facilitate more definitive metaanalyses.\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec28\" class=\"Section2\"\u003e \u003ch2\u003e4.3 Clinical Implications\u003c/h2\u003e \u003cp\u003e \u003col\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003e4.3.1 Routine Neurological Screening\u003c/b\u003e: Post-acute care protocols should incorporate neuroimaging (e.g., MRI for vascular injury), inflammatory biomarkers (e.g., IL-6, CRP), and validated cognitive assessments (e.g., MoCA) [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. High-risk populations, including those with severe acute infection or pre-existing vascular comorbidities, warrant prioritization [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e].\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003e4.3.2 Targeted Therapies\u003c/b\u003e: Endothelial stabilization (e.g., statins, antioxidants) and immunomodulation (e.g., anti-IL-6 agents) may mitigate neurovascular injury [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. Ambrosino et al. [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e] advocated for trials testing these strategies, given their mechanistic plausibility.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003e4.3.3 Multidisciplinary Care\u003c/b\u003e: Collaboration between neurologists, immunologists, and rehabilitation specialists is critical to address the multifactorial nature of sequelae [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e].\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003e4.3.4 MetaAnalysis Findings and Clinical Implications\u003c/b\u003e: The metaanalysis reinforces the narrative synthesis by quantitatively establishing significant associations between postacute COVID-19 and both neuroinflammatory markers and cerebrovascular risk. The statistically robust pooled effect sizes emphasize that these associations are not only consistent but also of considerable clinical relevance. These findings underscore the importance of integrating advanced neuroimaging, comprehensive inflammatory biomarker profiling, and standardized cognitive assessments into routine postacute COVID-19 screening protocols. Targeted therapeutic strategies such as interventions aimed at endothelial stabilization and immunomodulation could potentially mitigate the longterm neurological burden and improve patient outcomes.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003e4.3.5 Limitations\u003c/b\u003e: The heterogeneity of study designs and outcome measures limits cross-study comparability (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). Most evidence derived from observational studies [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e], which are susceptible to confounding. Additionally, follow-up durations were inconsistent (4 weeks to 6 months), with limited data on long-term outcomes beyond six months [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e].\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003c/ol\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec29\" class=\"Section2\"\u003e \u003ch2\u003e4.4 Implications for Future Research\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe current findings highlight several key areas for future investigation:\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003col\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003e4.4.1 Mechanistic Studies\u003c/b\u003e: Further research using animal models and human postmortem tissues is essential to elucidate the precise mechanisms linking neuroinflammation, endothelial dysfunction, and neurodegeneration.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003e4.4.2 Longitudinal Cohorts\u003c/b\u003e: Largescale, longitudinal studies are needed to map recovery trajectories and identify predictive biomarkers for longterm neurological outcomes.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003e4.4.3 Interventional Trials\u003c/b\u003e: There is a clear need for randomized controlled trials that evaluate the efficacy of targeted therapies such as antiIL-6 agents, statins, and novel NEMOpreserving compounds in mitigating postacute neurological sequelae.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003e4.4.4 Standardization of Outcome Measures\u003c/b\u003e: Future studies should adopt uniform outcome measures to enable more accurate comparisons across diverse populations and study designs.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003c/ol\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"5. Conclusions","content":"\u003cp\u003e\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003eThis systematic review and meta-analysis synthesize compelling evidence that post-acute COVID-19 neurological sequelae represents a multifaceted syndrome driven by the interplay of neuroimmune dysregulation, cerebrovascular injury, and cognitive dysfunction. The triad of pathologies sustained neuroinflammation (42% prevalence), cerebrovascular complications (22%), and cognitive deficits (58%) highlights the systemic and persistent impact of SARS-CoV-2 beyond acute infection (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e2\u003c/span\u003eA). Central to this cascade is the virus's capacity to trigger chronic immune activation, as evidenced by elevated pro-inflammatory cytokines (IL-6, TNF-α) and microglial hyperactivity [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e], alongside endothelial injury that compromises cerebral microcirculation and blood-brain barrier integrity [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. These mechanisms collectively disrupt neural homeostasis, fostering neurodegenerative processes such as grey matter atrophy [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e] and functional connectivity loss [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e], which manifest clinically as memory impairment, executive dysfunction, and debilitating \"brain fog\" [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eThe findings underscore the urgent need for a change in basic assumptions in post-COVID care. With over 700\u0026nbsp;million confirmed cases globally, the long-term neurological burden poses a significant public health challenge. Early identification through routine screening incorporating neuroimaging, biomarker profiling (e.g., IL-6, CRP, autoantibodies), and validated cognitive assessments are critical to mitigating disability [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. Furthermore, therapeutic strategies must pivot toward targeting shared pathways, such as endothelial stabilization (e.g., statins, NO donors) and immunomodulation (e.g., IL-6 inhibitors), to disrupt the neuroimmune-vascular axis [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. The experimental success of NEMO-preserving agents in mitigating BBB disruption [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e] offers a promising template for future drug development.\u003c/p\u003e\u003cp\u003eHowever, critical knowledge gaps persist. The heterogeneity of study designs limited long-term data (\u0026gt;\u0026thinsp;6 months), and reliance on observational evidence necessitate rigorous, harmonized research. Prioritizing standardized outcome measures such as the NIH Toolbox for cognitive testing or consensus-driven neuroimaging protocols will enhance cross-study comparability [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. Mechanistic studies exploring viral reservoirs in neural tissue [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e], autoantibody-mediated damage [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e], and sex-specific vulnerabilities (e.g., estrogen's neuroprotective role) are essential to refine therapeutic precision. Concurrently, large-scale longitudinal cohorts must track recovery trajectories across diverse populations, particularly in low-resource settings disproportionately affected by COVID-19 [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eThe neurological legacy of COVID-19 demands an initiative-taking, multidisciplinary response. Clinicians must integrate neurology into post-acute rehabilitation frameworks, while researchers and policymakers collaborate to address systemic inequities in care access. By unraveling the complex synergies between inflammation, vascular injury, and neurodegeneration, this review lays the groundwork for transformative interventions ultimately safeguarding cognitive health and quality of life for millions of survivors worldwide.\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e \u003ch2\u003eConflict of Interest\u003c/h2\u003e \u003cp\u003eNo potential conflict of interest relevant to this article was reported.\u003c/p\u003e \u003c/p\u003e\u003ch2\u003eFunding\u003c/h2\u003e \u003cp\u003eNo financial support or funding was received for the conduct of this review article.\u003c/p\u003e\u003ch2\u003eAcknowledgments\u003c/h2\u003e \u003cp\u003eI would like to extend my sincere gratitude to the faculty and instructors of the \u003cem\u003eHarvard Medical School Continuing Medical Education (CME) Program: Stroke and Other Neurological Conditions\u003c/em\u003e, accredited by the \u003cb\u003eAccreditation Council for Continuing Medical Education (ACCME)\u003c/b\u003e and offering \u003cb\u003eAMA PRA Category 1 Credits\u0026trade;\u003c/b\u003e, for their rigorous training and intellectual guidance. The advanced clinical insights and evidence-based frameworks provided through this program profoundly informed the methodological rigor and analytical depth of this systematic review. The expertise shared through this educational initiative enhanced my understanding of neurovascular pathophysiology and neuroinflammatory mechanisms, directly contributing to the conceptualization and interpretation of findings presented herein.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eDos RS, Sathish Selvam R, Ayyavoo V (2024) Neuroinflammation in post COVID-19 sequelae: neuroinvasion and neuroimmune crosstalk. Rev Med Virol 34(6). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/rmv.70009\u003c/span\u003e\u003cspan address=\"10.1002/rmv.70009\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDe Michele M, Kahan J, Berto I, Schiavo OG, Iacobucci M, Toni D, Merkler AE (2022) Cerebrovascular complications of COVID-19 and COVID-19 vaccination. Circ Res 130(8):1187\u0026ndash;1203. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1161/circresaha.122.319954\u003c/span\u003e\u003cspan address=\"10.1161/circresaha.122.319954\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eQuan M, Wang X, Gong M, Wang Q, Li Y, Jia J (2023) PostCOVID cognitive dysfunction: current status and research recommendations for high risk population. Lancet Reg Health West Pac 38:100836. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.lanwpc.2023.100836\u003c/span\u003e\u003cspan address=\"10.1016/j.lanwpc.2023.100836\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAmbrosino P, Calcaterra I, Mosella M, Formisano R, Silvestro Ennio D\u0026rsquo;Anna B, Bachetti T et al (2022) Endothelial dysfunction in COVID-19: a unifying mechanism and a potential therapeutic target. Biomedicines 10(4):812. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/biomedicines10040812\u003c/span\u003e\u003cspan address=\"10.3390/biomedicines10040812\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFekete M, Lehoczki A, Szappanos \u0026Aacute;T, Mahdi M, S\u0026oacute;tonyi P, Beny\u0026oacute; Z, Yabluchanskiy A, Tarantini S, Ungvari Z (2025) Cerebromicrovascular mechanisms contributing to long COVID: implications for neurocognitive health. GeroScience. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s11357-024-01487-4\u003c/span\u003e\u003cspan address=\"10.1007/s11357-024-01487-4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWijeratne T, Crewther S (2020) PostCOVID-19 neurological syndrome (PCNS); a novel syndrome with challenges for the global neurology community. J Neurol Sci 419:117179. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.jns.2020.117179\u003c/span\u003e\u003cspan address=\"10.1016/j.jns.2020.117179\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMathew B, Kumar R, Seetha Harilal, Sabitha M, Pappachan LK, Roshni PR (2021) Current perspective of COVID-19 on neurology: a mechanistic insight. Comb Chem High Throughput Screen 25(5):763\u0026ndash;767. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2174/1386207324666210805121828\u003c/span\u003e\u003cspan address=\"10.2174/1386207324666210805121828\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWenzel J, Lampe J, M\u0026uuml;llerFielitz H, Schuster R, Zille M, M\u0026uuml;ller K et al (2021) The SARSCoV-2 main protease M^pro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells. Nat Neurosci 24(11):1522\u0026ndash;1533. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41593-021-00926-1\u003c/span\u003e\u003cspan address=\"10.1038/s41593-021-00926-1\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSchwabenland M, Sali\u0026eacute; H, Tanevski J, Killmer S, Lago MS, Schlaak AE, Mayer L et al (2021) Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microgliaTcell interactions. Immunity 54(7):1594\u0026ndash;1610e11. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.immuni.2021.06.002\u003c/span\u003e\u003cspan address=\"10.1016/j.immuni.2021.06.002\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAlAly Z, Xie Y, Bowe B (2021) Highdimensional characterisation of postacute sequelae of COVID-19. Nature 594:1\u0026ndash;8. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41586-021-03553-9\u003c/span\u003e\u003cspan address=\"10.1038/s41586-021-03553-9\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDouaud G, Lee S, AlfaroAlmagro F, Arthofer C, Wang C, McCarthy P et al (2022) SARSCoV-2 is associated with changes in brain structure in UK Biobank. Nature 604(7907). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41586-022-04569-5\u003c/span\u003e\u003cspan address=\"10.1038/s41586-022-04569-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWaters BL, Michalak AJ, Brigham D, Thakur KT, Boehme A, Claassen J, Bell M (2021) Incidence of electrographic seizures in patients with COVID-19. Front Neurol 12:614719. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fneur.2021.614719\u003c/span\u003e\u003cspan address=\"10.3389/fneur.2021.614719\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGonzalezFernandez E, Huang J (2023) Cognitive aspects of COVID-19. Curr Neurol Neurosci Rep 23(9):531\u0026ndash;538. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s11910-023-01286-y\u003c/span\u003e\u003cspan address=\"10.1007/s11910-023-01286-y\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRahman MA, Islam K, Rahman S, Alamin M (2020) Neurobiochemical crosstalk between COVID-19 and Alzheimer\u0026rsquo;s disease. Mol Neurobiol. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s12035-020-02177-w\u003c/span\u003e\u003cspan address=\"10.1007/s12035-020-02177-w\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKausel L, FigueroaVargas A, Zamorano F, Stecher X, Asp\u0026eacute;S\u0026aacute;nchez M, CarvajalParedes P et al (2024) Patients recovering from COVID-19 who presented with anosmia during their acute episode have behavioural, functional and structural brain alterations. Sci Rep 14(1). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41598-024-69772-y\u003c/span\u003e\u003cspan address=\"10.1038/s41598-024-69772-y\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"University of the People | Harvard Medical School - CME","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"SARSCoV-2, COVID-19, neuroinflammation, cerebrovascular complications, cognitive dysfunction, postacute outcomes, systematic review","lastPublishedDoi":"10.21203/rs.3.rs-6183335/v2","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-6183335/v2","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eSARS-CoV-2, initially identified as a respiratory pathogen, has emerged as a significant driver of neurological morbidity in the post-acute phase of infection. A substantial body of evidence underscores persistent neuroimmune dysregulation, cerebrovascular injury, and cognitive impairment as critical contributors to long-term disability among COVID-19 survivors. However, the mechanistic interplay between these processes and their clinical implications remains incompletely characterized.\u003c/p\u003e\u003ch2\u003eObjectives\u003c/h2\u003e \u003cp\u003eThis systematic review and meta-analysis aim to (1) elucidate the pathophysiological mechanisms underlying post-acute neurological outcomes of COVID-19, (2) evaluate the prevalence and clinical spectrum of neuroimmune, cerebrovascular, and cognitive disturbances using both qualitative and quantitative data, and (3) propose strategies for early detection and clinical management based on rigorous, evidence-based findings.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eA comprehensive search of PubMed, EMBASE, and the Cochrane Library was conducted for studies published between January 1, 2020, and January 31, 2025. Included studies reported on neuroinflammatory biomarkers, cerebrovascular events, or cognitive dysfunction assessed\u0026thinsp;\u0026ge;\u0026thinsp;4 weeks after acute SARS-CoV-2 infection. Two independent reviewers screened records, extracted data, and appraised study quality using PRISMA 2020 guidelines. A narrative synthesis was supplemented by a quantitative meta-analysis of key outcomes, with pooled effect estimates calculated using random-effects models to address heterogeneity.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eFrom 2,178 screened records, 10 studies (n\u0026thinsp;\u0026asymp;\u0026thinsp;77,300) met the inclusion criteria. Three interrelated pathological domains were identified: (1) Neuroimmune Dysregulation: Persistent cytokine elevations (e.g., IL-6, TNF-α), microglial activation, and neuronal autoantibodies (detected in ~\u0026thinsp;18% of patients) indicate a state of chronic neuroinflammation. (2) Cerebrovascular Complications: A 3.7-fold increased risk of stroke, along with evidence of blood\u0026ndash;brain barrier (BBB) disruption and microvascular injury, underscores the role of endothelial dysfunction and thromboinflammatory pathways. (3) Cognitive Dysfunction: Deficits in memory, executive function, and processing speed, reported in up to 58% of patients, correlated with neuroimaging findings of grey matter atrophy and altered functional connectivity. The meta-analysis yielded a pooled standardized mean difference for IL-6 elevation of 0.78 (95% CI: 0.55\u0026ndash;1.01; p\u0026thinsp;\u0026lt;\u0026thinsp;0.001) and a pooled odds ratio for stroke risk of 3.7 (95% CI: 2.1\u0026ndash;6.4; p\u0026thinsp;\u0026lt;\u0026thinsp;0.001). Moderate-to-high heterogeneity (I\u0026sup2; between 50% and 70%) was addressed using random-effects models and sensitivity analyses, which confirmed the robustness of these associations.\u003c/p\u003e\u003ch2\u003eConclusions\u003c/h2\u003e \u003cp\u003ePost-acute COVID-19 manifests as a triad of neuroimmune, vascular, and cognitive disturbances, supported by both narrative and quantitative analyses. Early identification through multimodal screening including advanced neuroimaging, comprehensive inflammatory biomarker profiling, and validated cognitive assessments are essential. Targeted therapeutic strategies focusing on endothelial stabilization and immunomodulation may prove pivotal in mitigating long-term disability. Future research should prioritize standardized outcome measures and mechanistic studies to further refine interventional approaches and inform clinical policy.\u003c/p\u003e","manuscriptTitle":"Investigating the Neuroimmune, Cerebrovascular, and Cognitive Disturbances Associated with SARS‑CoV‑2 Infection: A Systematic Review of Post‑Acute Outcomes","msid":"","msnumber":"","nonDraftVersions":[{"code":2,"date":"2025-03-21 16:33:16","doi":"10.21203/rs.3.rs-6183335/v2","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}},{"code":1,"date":"2025-03-11 06:47:10","doi":"10.21203/rs.3.rs-6183335/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"4bf2b82e-dc62-41ed-a490-95d78e187eb9","owner":[],"postedDate":"March 21st, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-04-03T20:43:45+00:00","versionOfRecord":[],"versionCreatedAt":"2025-03-21 16:33:16","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v2","identity":"rs-6183335","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-6183335","identity":"rs-6183335","version":["v2"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}